Immunic Inc
NASDAQ:IMUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hitachi Energy India Ltd
NSE:POWERINDIA
|
IN |
|
Aptargroup Inc
NYSE:ATR
|
US |
|
Teledyne Technologies Inc
NYSE:TDY
|
US |
Immunic Inc
Other Items
Immunic Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunic Inc
NASDAQ:IMUX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Other Items
-€1.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-96%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Other Items
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Other Items
€211.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Other Items
-€16.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
19%
|
|
|
Formycon AG
XETRA:FYB
|
Other Items
€28.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
228%
|
|
Immunic Inc
Glance View
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
